KEYNOTE-B49
What it tests: Pembrolizumab versus placebo, both combined with chemotherapy, in HR+/HER2− advanced breast cancer. Randomized, double-blind phase 3 study.

Listen to Oncology Here & Now
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletterWhat it tests: Pembrolizumab versus placebo, both combined with chemotherapy, in HR+/HER2− advanced breast cancer. Randomized, double-blind phase 3 study.
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.